You have 9 free searches left this month | to do more
Showing 1 - 25 of
1,459 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
K
Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS
Not yet recruiting
  • Preleukemia
  • +2 more
  • Copenhagen, Copenhagen N, Denmark
    Rigshospitalet
2021-02-04
Feb 4, 2021
N
BMS-986253 in Myelodysplastic Syndromes
Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-13
Jan 13, 2022
F
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
Withdrawn
  • Myelodysplastic Syndrome (MDS)
  • (no location specified)
2021-07-20
Jul 20, 2021
T
Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes
No longer available
  • Myelodysplastic Syndromes
  • (no location specified)
2021-09-08
Sep 8, 2021
T
Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly
Recruiting
  • Myelodysplastic Syndromes
  • Observational
  • Dresden, Germany
  • +1 more
2021-08-10
Aug 10, 2021
A
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
Recruiting
  • Myelodysplastic Syndrome
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-07-21
Jul 21, 2021
U
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
Recruiting
  • Myelodysplastic Syndromes
    • Toulouse, France
      IUCT-Oncopole University Hospital
    2021-03-16
    Mar 16, 2021
    S
    SNS-301 Monotherapy in High Risk MDS and CMML
    Withdrawn
    • Myelodysplastic Syndromes
    • Chronic Myelomonocytic Leukemia (CMML)
    • (no location specified)
    2021-08-09
    Aug 9, 2021
    C
    Revlimid in Transfusion Dependent Patients
    Active, not recruiting
    Has Results
    • Myelodysplastic Syndrome
    • Revlimid (Lenalidomide)
    • New York, New York
      Columbia University Medical Center
    2021-06-30
    Jun 30, 2021
    U
    Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
    Recruiting
    • High Grade Myelodysplastic Syndromes
    • Aurora, Colorado
      Universtiy of Colorado Denver
    2021-10-19
    Oct 19, 2021
    N
    Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
    Recruiting
    • Myelodysplasia
    • Hematologic Malignancy
    • CliniMACS® TCRαβ/CD19 Combined Depletion System
    • Columbus, Ohio
      Nationwide Children's Hospital
    2022-01-11
    Jan 11, 2022
    D
    The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study - 2020
    Completed
    • Myelodysplastic Syndromes (MDS)
      • Boston, Massachusetts
      • +2 more
      2022-01-06
      Jan 6, 2022
      T
      A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
      Withdrawn
      • Myelodysplastic Syndromes (MDS)
      • (no location specified)
      2021-09-23
      Sep 23, 2021
      C
      Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)
      Not yet recruiting
      • Myelodysplastic Syndromes
      • Beta-thalassemia
        • (no location specified)
        2021-07-13
        Jul 13, 2021
        P
        RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
        Recruiting
        • Myelodysplastic Syndromes
        • Beijing, Beijing, China
          Peking University Institute of Hematology,Beijing
        2021-09-14
        Sep 14, 2021
        U
        A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
        Active, not recruiting
        • Myelodysplastic Syndromes
        • Chronic Myelomonocytic Leukemia
        • Rochester, New York
          University of Rochester
        2022-01-04
        Jan 4, 2022
        D
        Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS - 2021
        Completed
        • Myelodysplastic Syndromes
        • Peri-Transfusion QOL Assessment
        • Boston, Massachusetts
          Dana Farber Cancer Institute
        2022-01-06
        Jan 6, 2022
        U
        Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
        Recruiting
        • Myelodysplasia
        • Grenoble, France
          CHU de GRENOBLE ALPES
        2021-10-01
        Oct 1, 2021
        W
        Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
        Active, not recruiting
        • Myelodysplastic Syndromes
        • Saint Louis, Missouri
          Washington University School of Medicine
        2021-06-15
        Jun 15, 2021
        U
        Biocollection in MyeloDysplastic Syndrome (P-MDS)
        Not yet recruiting
        • Myelodysplastic Syndromes
        • +5 more
        • description of MDS pzatient cohort
        • (no location specified)
        2021-04-30
        Apr 30, 2021
        T
        Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome
        Recruiting
        • Myelodysplastic Syndromes
        • Medical Device Usage and Evaluation
        • +3 more
        • Philadelphia, Pennsylvania
          Sidney Kimmel Cancer Center at Thomas Jefferson University
        2021-07-19
        Jul 19, 2021
        N
        Biology Studies of Hematologic Cancers
        Enrolling by invitation
        • Acute Lymphoblastic Leukemia
        • +4 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          2021-12-15
          Dec 15, 2021
          S
          Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
          Suspended
          • Myelodysplastic Syndromes
          • Allogeneic umbilical cord mesenchymal stem cells
          • Decitabine
          • Hohhot, Inner Mongolia, China
            Inner Mongolia International Mongolian Hospital
          2021-09-21
          Sep 21, 2021
          M
          Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
          Active, not recruiting
          • High Risk Myelodysplastic Syndrome
          • Houston, Texas
            M D Anderson Cancer Center
          2021-05-06
          May 6, 2021
          N
          SCT Plus Immune Therapy in Average Risk AML/MDS
          Active, not recruiting
          • Acute Myelogenous Leukemia
          • Myelodysplastic Syndrome
          • Gemtuzumab Ozogamicin
          • Valhalla, New York
            New York Medical College
          2021-11-11
          Nov 11, 2021